Exelixis (EXEL) - Stock Price & Dividends

Exelixis Inc. (NASDAQ: EXEL) is a company that specializes in oncology, with a primary focus on discovering, developing, and bringing to market new medications for challenging cancer types in the United States.

Their product offerings include CABOMETYX tablets for advanced renal cell carcinoma patients who have undergone prior anti-angiogenic therapy, as well as COMETRIQ capsules for those with progressive and metastatic medullary thyroid cancer. These treatments are derived from cabozantinib, which acts as an inhibitor of various tyrosine kinases such as MET, AXL, RET, and VEGF receptors.

Additionally, Exelixis provides COTELLIC, a MEK inhibitor used in combination to address specific advanced melanoma forms, and MINNEBRO, a non-steroidal selective blocker of the mineralocorticoid receptor designed for hypertension treatment in Japan.

The company is also actively engaged in developing innovative therapies like zanzalintinib, a potent oral tyrosine kinase inhibitor directed towards VEGF receptors, MET, and TAM kinases (TYRO3, AXL, and MER). Furthermore, their pipeline includes XB002, a next-generation ADC that targets tissue factor, with research collaborations and license agreements with various prominent pharmaceutical entities.

Established in 1994 and based in Alameda, California, Exelixis Inc. operates with a mission to advance cancer treatment through groundbreaking research and strategic partnerships in the field of oncology. For more information, visit their official website at https://www.exelixis.com.